Pharmaceutical conglomerate AbbVie–the maker of AndroGel–has asked the Court to grant it summary judgment in the 3 remaining AndroGel-related cases. The company pulled out a variety arguments in an attempt to avoid trial in the matters.
Summary judgment motions are an opportunity for a defendant to argue to the Court that they should be able to avoid a jury trial because the plaintiff is lacking evidence on some point. However, they are very frequently abused by corporate defendants who file such motions in every case, no matter how strong the evidence is against them.
The 3 AndroGel plaintiffs have filed extensive oppositions to AbbVie’s motions, painstakingly pointing out they have evidence showing AndroGel caused their heart attacks and strokes and that the company knew or should have known about the dangers long before marketing AndroGel as a lifestyle drug.
Plaintiffs are very confident that once the Court reviews the material, it will rule in their favor and deny AbbVie’s motions.